Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03284957
Title Phase 1 / 2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Sanofi

breast adenocarcinoma



Alpelisib + Amcenestrant

Amcenestrant + Palbociclib

Abemaciclib + Amcenestrant

Amcenestrant + Everolimus

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | CAN | BEL

No variant requirements are available.